MXPA05007495A - Tienopiridazinonas y su uso en la modulacion de enfermedades autoinmunes. - Google Patents

Tienopiridazinonas y su uso en la modulacion de enfermedades autoinmunes.

Info

Publication number
MXPA05007495A
MXPA05007495A MXPA05007495A MXPA05007495A MXPA05007495A MX PA05007495 A MXPA05007495 A MX PA05007495A MX PA05007495 A MXPA05007495 A MX PA05007495A MX PA05007495 A MXPA05007495 A MX PA05007495A MX PA05007495 A MXPA05007495 A MX PA05007495A
Authority
MX
Mexico
Prior art keywords
thienopyridazinones
modulation
autoimmune disease
formula
therapy
Prior art date
Application number
MXPA05007495A
Other languages
English (en)
Inventor
David Guile Simon
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0300118A external-priority patent/SE0300118D0/xx
Priority claimed from SE0300117A external-priority patent/SE0300117D0/xx
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MXPA05007495A publication Critical patent/MXPA05007495A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Abstract

La presente invencion se refiere al compuesto de tienopiridazinonas de la formula (I) en donde R1, R2 y Q son como se definen en la especificacion, y Ar y Ar2 se seleccionan de ciertos sistemas de anillos aromaticos los cuales pueden ser opcionalmente sustituidos, como se define en la especificacion: Procesos para la preparacion de compuestos de formula (I), tambien se describen y reivindican composiciones farmaceuticas que los contienen y su uso en terapia.
MXPA05007495A 2003-01-17 2004-01-15 Tienopiridazinonas y su uso en la modulacion de enfermedades autoinmunes. MXPA05007495A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0300118A SE0300118D0 (sv) 2003-01-17 2003-01-17 Novel Compounds
SE0300117A SE0300117D0 (sv) 2003-01-17 2003-01-17 Novel Compounds
PCT/SE2004/000053 WO2004065395A1 (en) 2003-01-17 2004-01-15 Thienopyridazinones and their use in modulation of autoimmune disease

Publications (1)

Publication Number Publication Date
MXPA05007495A true MXPA05007495A (es) 2005-09-21

Family

ID=32775326

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05007495A MXPA05007495A (es) 2003-01-17 2004-01-15 Tienopiridazinonas y su uso en la modulacion de enfermedades autoinmunes.

Country Status (15)

Country Link
US (2) US7393854B2 (es)
EP (1) EP1587811A1 (es)
JP (1) JP2006515880A (es)
KR (1) KR20050092761A (es)
AU (1) AU2004206011B2 (es)
BR (1) BRPI0406782A (es)
CA (1) CA2512136A1 (es)
IL (1) IL169369A0 (es)
IS (1) IS7962A (es)
MX (1) MXPA05007495A (es)
NO (1) NO20053825L (es)
NZ (1) NZ541218A (es)
PL (1) PL378221A1 (es)
RU (1) RU2332420C2 (es)
WO (1) WO2004065395A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0117583D0 (en) * 2001-07-19 2001-09-12 Astrazeneca Ab Novel compounds
GB0118479D0 (en) * 2001-07-28 2001-09-19 Astrazeneca Ab Novel compounds
PL378221A1 (pl) * 2003-01-17 2006-03-20 Astrazeneca Ab Tienopirydazynony i ich zastosowanie w modulacji choroby autoimmunologicznej
SE0300120D0 (sv) * 2003-01-17 2003-01-17 Astrazeneca Ab Novel compounds
SE0300119D0 (sv) * 2003-01-17 2003-01-17 Astrazeneca Ab Novel compounds
KR102228034B1 (ko) * 2013-10-21 2021-03-16 제노스코 치환된 피리미딘 화합물 및 syk 억제제로서의 이의 용도
UY36586A (es) * 2015-03-26 2016-10-31 Bayer Pharma AG Heterociclilmetiltienouracilos y uso de los mismos

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9702001D0 (sv) * 1997-05-28 1997-05-28 Astra Pharma Prod Novel compounds
US6984644B2 (en) * 1997-05-28 2006-01-10 Astrazeneca Ab Treatment of skin disorders using thieno[2,3-D]pyrimidinediones
US6469014B1 (en) * 1997-05-28 2002-10-22 Astrazeneca Ab Thieno[2,3-d] pyrimidinediones, their preparation and use in therapy
PL340836A1 (en) 1997-12-05 2001-02-26 Astrazeneca Uk Ltd Novel compounds
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
US6233320B1 (en) * 1998-06-22 2001-05-15 Lucent Technologies Inc. Method and apparatus for recording and playing back a conversation using a digital wireless phone
WO2000012514A1 (en) 1998-08-28 2000-03-09 Astrazeneca Ab Novel compounds
DE60104677T2 (de) * 2000-05-04 2005-07-28 Astrazeneca Ab THIENO[2,3-d]PYRIMIDINDIONE UND IHRE VERWENDUNG ALS PHARMAZEUTISCHE MITTEL
GB0117583D0 (en) * 2001-07-19 2001-09-12 Astrazeneca Ab Novel compounds
GB0118479D0 (en) * 2001-07-28 2001-09-19 Astrazeneca Ab Novel compounds
PL378221A1 (pl) * 2003-01-17 2006-03-20 Astrazeneca Ab Tienopirydazynony i ich zastosowanie w modulacji choroby autoimmunologicznej
SE0300119D0 (sv) * 2003-01-17 2003-01-17 Astrazeneca Ab Novel compounds
SE0300120D0 (sv) 2003-01-17 2003-01-17 Astrazeneca Ab Novel compounds

Also Published As

Publication number Publication date
PL378221A1 (pl) 2006-03-20
US20080221131A1 (en) 2008-09-11
JP2006515880A (ja) 2006-06-08
IL169369A0 (en) 2007-07-04
RU2332420C2 (ru) 2008-08-27
WO2004065395A1 (en) 2004-08-05
EP1587811A1 (en) 2005-10-26
US20060135539A1 (en) 2006-06-22
BRPI0406782A (pt) 2006-01-17
NZ541218A (en) 2008-05-30
KR20050092761A (ko) 2005-09-22
IS7962A (is) 2005-07-27
AU2004206011B2 (en) 2007-07-12
RU2005121492A (ru) 2006-02-10
NO20053825D0 (no) 2005-08-15
AU2004206011A1 (en) 2004-08-05
CA2512136A1 (en) 2004-08-05
US7393854B2 (en) 2008-07-01
NO20053825L (no) 2005-10-17

Similar Documents

Publication Publication Date Title
EG25613A (en) Thienopyrimidinediones and their use in the modulation of autoimmune disease
DE602004021472D1 (en) Pyrimiidinverbindungen
AU2003228770A8 (en) Substituted pyrazolopyrimidines
MXPA05012025A (es) Imidazo y tiazolopiridinas como inhibidores de cinasa jak3.
MXPA03010207A (es) Nuevas 4-anilinoquinolin-3-carboxamidas.
TW200621737A (en) 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof
SE0200920D0 (sv) Novel compounds
WO2004106293A3 (en) Oxazolyl - and thiazolyl - purine based tricyclic compounds.
SE0302139D0 (sv) Novel compounds
MY135850A (en) Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds and their use
TW200604197A (en) New compounds
IL160171A0 (en) Depsipeptide derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
NO20053825L (no) Thienopyridazinoner og deres anvendelse ved modulering av autoimmune sykdommer.
WO2004075846A3 (en) Pyrazolopurine-based tricyclic compounds and pharmaceutical compositions comprising same
IL172538A0 (en) Depsipeptide compounds, pharmaceutical compositions containing the same and processes for the preparation thereof
WO2005011609A3 (en) Triazolopurine-based tricyclic compounds and pharmaceutical compositions comprising same
SE0303280D0 (sv) Novel compounds
EA200600992A1 (ru) Амиды тиазолидинона, амиды тиазолидинкарбоновой кислоты, способы их получения и их применение
WO2004087652A3 (en) Imidazotriazine compounds
IL165220A0 (en) Novel compounds, their use and preparation
DE60201074D1 (en) Pyrazolopyridinderivate
SE0302755D0 (sv) Novel compounds
SE9904128D0 (sv) Novel compounds
AU2002357740A1 (en) Pyrazolo-pyridine derivatives as antiherpes agents
SE0300117D0 (sv) Novel Compounds

Legal Events

Date Code Title Description
FG Grant or registration